Assessment of the safety and effectiveness of neoadjuvant camrelizumab and apatinib in conjunction with chemotherapy for stage IIIA (N2) non-small cell lung cancer: Results from a multi-center, single-arm phase II study - Scorecard - MDSpire

Assessment of the safety and effectiveness of neoadjuvant camrelizumab and apatinib in conjunction with chemotherapy for stage IIIA (N2) non-small cell lung cancer: Results from a multi-center, single-arm phase II study

  • By

  • Lilan Zhao

  • Tianxing Guo

  • Yi Zhang

  • Zhen Huang

  • Yangyun Huang

  • Lihuan Zhu

  • Xing Chen

  • Nan Zhang

  • Liren Guo

  • Rongzhi Huang

  • Guojun Geng

  • Ning Li

  • Shuxing Chen

  • Xiaojie Pan

  • Wenshu Chen

  • October 24, 2025

  • 0 min

Share

Clinical Scorecard: Assessment of the safety and effectiveness of neoadjuvant camrelizumab and apatinib in conjunction with chemotherapy for stage IIIA (N2) non-small cell lung cancer: Results from a multi-center, single-arm phase II study

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target Population
Care SettingMulti-center, open-label, phase 2 trial conducted in China across four hospitals.

Key Highlights

  • Study aimed to assess safety and efficacy prior to surgical intervention, focusing on specific outcomes such as tumor response rates and adverse events.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Enhanced CT scan of the chest after the first two treatment cycles, with follow-up assessments every two cycles.

      Risks

        Patient & Prescribing Data

        Combination therapy aims to reduce recurrence rates and improve surgical outcomes, with attention to potential side effects such as immune-related adverse events.

        Clinical Best Practices

        • Conduct comprehensive assessments for resectability by a multidisciplinary team, including oncologists, surgeons, and radiologists.

        Related Resources & Content

        Original Source(s)

        Assessment of the safety and effectiveness of neoadjuvant camrelizumab and apatinib in conjunction with chemotherapy for stage IIIA (N2) non-small cell lung cancer: Results from a multi-center, single-arm phase II study

        • by Lilan Zhao, Tianxing Guo, Yi Zhang, Zhen Huang, Yangyun Huang, Lihuan Zhu, Xing Chen, Nan Zhang, Liren Guo, Rongzhi Huang, Guojun Geng, Ning Li, Shuxing Chen, Xiaojie Pan, Wenshu Chen

        • October 24, 2025

        Related Content

        Editorial: Importance of quality assurance in radiation oncology clinical trials

        Editorial: Cancer Immunosurveillance

        Advances in neoadjuvant immunotherapy for non-small cell lung cancer